Total baseline tumor size predicts survival among patients with advanced small-cell lung cancer receiving chemotherapy plus programmed death-ligand 1 inhibitor as first-line therapy: a multicenter retrospective observational study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Total baseline tumor size (BTS) impacts survival in small-cell lung cancer (SCLC) patients receiving chemotherapy plus PD-L1 inhibitors. Larger BTS indicates worse overall survival, identifying it as a negative prognostic factor.
Area Of Science
- Oncology
- Medical Research
- Clinical Trials
Background
- Total baseline tumor size (BTS) is a known prognostic factor for programmed death 1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitor treatments.
- The prognostic significance of total BTS in small-cell lung cancer (SCLC) patients treated with chemotherapy plus PD-L1 inhibitors is not well-established.
Purpose Of The Study
- To investigate the association between total baseline tumor size (BTS) and prognosis in patients with SCLC receiving first-line chemotherapy plus PD-L1 inhibitor therapy.
Main Methods
- Retrospective study of 50 patients with extensive-stage SCLC or recurrent limited-stage SCLC receiving first-line chemotherapy plus PD-L1 inhibitor.
- Total BTS calculated by summing the diameters of up to 10 largest lesions across five organs.
- Patients categorized into large or small BTS groups using X-tile software; survival analyzed via Kaplan-Meier and log-rank tests; prognostic factors assessed by univariate and multivariate analyses.
Main Results
- 14% of patients had large total BTS (>183.2 mm), while 86% had small total BTS (≤183.2 mm).
- Patients with large total BTS exhibited significantly worse overall survival (median 5.7 months) compared to those with small total BTS (median 26.8 months; P = 0.0003).
- Multivariate analysis identified large total BTS as an independent negative predictor of overall survival (HR: 7.14, 95% CI: 1.89-26.96).
Conclusions
- Total baseline tumor size (BTS) is a significant prognostic factor for patients with advanced SCLC treated with first-line chemotherapy plus PD-L1 inhibitors.
- Larger total BTS is associated with poorer overall survival in this patient population.
- Total BTS may serve as a valuable tool for risk stratification and treatment planning in advanced SCLC.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.